Cover Image

Antibody-mediated therapy against HIV/AIDS: Where are we standing now?

Acquired immunodeficiency syndrome (AIDS) cases are on the rise globally. To date, there is still no effective measure to eradicate the causative agent, human immunodeficiency virus (HIV). Highly active antiretroviral therapy (HAART) is being used in HIV/AIDS management, but it results in long-term...

Full description

Saved in:
Bibliographic Details
Main Authors: Awi, Noel Jacques *, Teow, Sin Yeang *
Format: Article
Language:English
Published: Hindawi Publishing 2018
Subjects:
R Medicine (General)
RM Therapeutics. Pharmacology
Online Access:http://eprints.sunway.edu.my/835/1/Ronald%20Teow%20Antibody-mediated%20therapy%20against%20HIV%20AIDS%20Where%20are%20we%20standing%20now.pdf
http://eprints.sunway.edu.my/835/
http://doi.org/10.1155/2018/8724549
Tags: Add Tag
No Tags, Be the first to tag this record!
id my.sunway.eprints.835
record_format eprints
spelling my.sunway.eprints.8352019-04-22T05:26:54Z http://eprints.sunway.edu.my/835/ Antibody-mediated therapy against HIV/AIDS: Where are we standing now? Awi, Noel Jacques * Teow, Sin Yeang * R Medicine (General) RM Therapeutics. Pharmacology Acquired immunodeficiency syndrome (AIDS) cases are on the rise globally. To date, there is still no effective measure to eradicate the causative agent, human immunodeficiency virus (HIV). Highly active antiretroviral therapy (HAART) is being used in HIV/AIDS management, but it results in long-term medication and has major drawbacks such as multiple side effects, high cost, and increasing the generation rate of escape mutants. In addition, HAART does not control HIV-related complications, and hence more medications and further management are required. With this, other alternatives are urgently needed. In the past, small molecule inhibitors have shown potent antiviral effects, and some of them are now being evaluated in clinical trials. The challenges in developing these small molecules for clinical use include the off-target effect, poor stability, and low bioavailability. On the other hand, antibody-mediated therapy has emerged as an important therapeutic modality for anti-HIV therapeutics development. Many antiviral antibodies, namely, broad neutralizing antibodies (bnAbs) against multiple strains of HIV, have shown promising effects in vitro and in animal studies; further studies are ongoing in clinical trials to evaluate their uses in clinical applications. This short review aims to discuss the current development of therapeutic antibodies against HIV and the challenges in adopting them for clinical use. Hindawi Publishing 2018-06-03 Article PeerReviewed text en cc_by_nc_4 http://eprints.sunway.edu.my/835/1/Ronald%20Teow%20Antibody-mediated%20therapy%20against%20HIV%20AIDS%20Where%20are%20we%20standing%20now.pdf Awi, Noel Jacques * and Teow, Sin Yeang * (2018) Antibody-mediated therapy against HIV/AIDS: Where are we standing now? Journal of Pathogens, 2018. pp. 1-9. ISSN 2090-3057 http://doi.org/10.1155/2018/8724549 doi:10.1155/2018/8724549
institution Sunway University
building Sunway Campus Library
collection Institutional Repository
continent Asia
country Malaysia
content_provider Sunway University
content_source Sunway Institutional Repository
url_provider http://eprints.sunway.edu.my/
language English
topic R Medicine (General)
RM Therapeutics. Pharmacology
spellingShingle R Medicine (General)
RM Therapeutics. Pharmacology
Awi, Noel Jacques *
Teow, Sin Yeang *
Antibody-mediated therapy against HIV/AIDS: Where are we standing now?
description Acquired immunodeficiency syndrome (AIDS) cases are on the rise globally. To date, there is still no effective measure to eradicate the causative agent, human immunodeficiency virus (HIV). Highly active antiretroviral therapy (HAART) is being used in HIV/AIDS management, but it results in long-term medication and has major drawbacks such as multiple side effects, high cost, and increasing the generation rate of escape mutants. In addition, HAART does not control HIV-related complications, and hence more medications and further management are required. With this, other alternatives are urgently needed. In the past, small molecule inhibitors have shown potent antiviral effects, and some of them are now being evaluated in clinical trials. The challenges in developing these small molecules for clinical use include the off-target effect, poor stability, and low bioavailability. On the other hand, antibody-mediated therapy has emerged as an important therapeutic modality for anti-HIV therapeutics development. Many antiviral antibodies, namely, broad neutralizing antibodies (bnAbs) against multiple strains of HIV, have shown promising effects in vitro and in animal studies; further studies are ongoing in clinical trials to evaluate their uses in clinical applications. This short review aims to discuss the current development of therapeutic antibodies against HIV and the challenges in adopting them for clinical use.
format Article
author Awi, Noel Jacques *
Teow, Sin Yeang *
author_facet Awi, Noel Jacques *
Teow, Sin Yeang *
author_sort Awi, Noel Jacques *
title Antibody-mediated therapy against HIV/AIDS: Where are we standing now?
title_short Antibody-mediated therapy against HIV/AIDS: Where are we standing now?
title_full Antibody-mediated therapy against HIV/AIDS: Where are we standing now?
title_fullStr Antibody-mediated therapy against HIV/AIDS: Where are we standing now?
title_full_unstemmed Antibody-mediated therapy against HIV/AIDS: Where are we standing now?
title_sort antibody-mediated therapy against hiv/aids: where are we standing now?
publisher Hindawi Publishing
publishDate 2018
url http://eprints.sunway.edu.my/835/1/Ronald%20Teow%20Antibody-mediated%20therapy%20against%20HIV%20AIDS%20Where%20are%20we%20standing%20now.pdf
http://eprints.sunway.edu.my/835/
http://doi.org/10.1155/2018/8724549
_version_ 1644324413562159104
score 13.211869

Similar Items